<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999660</url>
  </required_header>
  <id_info>
    <org_study_id>Space-CS-01</org_study_id>
    <nct_id>NCT01999660</nct_id>
  </id_info>
  <brief_title>Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™</brief_title>
  <official_title>Prospective National Post-marketing Surveillance for the Investigation of the Efficacy and Safety of SpaceOAR™ to Maintain Space Between the Rectum and Prostate During Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CS Diagnostics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aix Scientifics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CS Diagnostics GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation&#xD;
      therapy in prostate cancer patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The degradable SpaceOAR™ hydrogel establishes for the time of radiotherapy a distance between&#xD;
      the prostate and the rectum&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI did leave hospital (retired)&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">August 2019</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the rectal complication rate (late toxicity)</measure>
    <time_frame>6 months and yearly for 5 years thereafter</time_frame>
    <description>the rectal complication rate following the common toxicity criteria (CTC) v. 2.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months and for 5 years yearly thereafter</time_frame>
    <description>The validated Expanded Prostate Cancer Index Composite (EPIC) questionnaire in combination with the validated Short Form Health Survey (SF-12) will be used to document the influence on the quality of life (QoL).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>feasibility of the implantation procedure</measure>
    <time_frame>1 day</time_frame>
    <description>feasibility of the implantation procedure will be documented by subjective description given by the investigators. this includes safety aspects.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">119</enrollment>
  <condition>Prostate Cancer Patients Treated by Radiotherapy</condition>
  <arm_group>
    <arm_group_label>SpaceOAR™</arm_group_label>
    <description>prostate cancer patient prophetically treated by SpaceOAR™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpaceOAR™ implantation</intervention_name>
    <arm_group_label>SpaceOAR™</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        prostate cancer patients treated by radiotherapy and prophetically by SpaceOAR™&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is suffering from pathologically confirmed T1-T2, N0, M0 prostate&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  Patient is intended to receive radiation therapy (3D-computerized radiotherapy,&#xD;
             intensity-modulated radiotherapy, and/or brachytherapy) and this will be the first&#xD;
             prostate or pelvic radiation therapy.&#xD;
&#xD;
          -  Patient is intended to receive SpaceOAR™ Gel therapy.&#xD;
&#xD;
          -  The patient is official patient of the clinical investigator in the study centre.&#xD;
&#xD;
          -  Patient agrees to fully participate in the clinical trial and give informed consent in&#xD;
             writing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anatomic abnormality, physical or pathological condition precluding the implantation.&#xD;
&#xD;
          -  Failure in the wall of the perineum room (with the risk that the hydrogel escapes).&#xD;
&#xD;
          -  History of prostate surgery or local prostate cancer therapy.&#xD;
&#xD;
          -  Rectal injury before implantation of SpaceOAR™ Gel or history of or active&#xD;
             inflammatory rectal disease such as Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          -  History of or current perirectal or anal disease or surgery such as prolapsed or&#xD;
             bleeding haemorrhoids or fistula.&#xD;
&#xD;
          -  Compromised immune system (e.g., HIV/acquired immunodeficiency syndrome, auto¬immune&#xD;
             disease or immunosuppressive therapy).&#xD;
&#xD;
          -  Platelet count, partial thromboplastin time, or white blood cell count out of normal&#xD;
             laboratory range.&#xD;
&#xD;
          -  Contraindication for safe MRI and CT scans.&#xD;
&#xD;
          -  Patient is not able to fully participate in this study including the follow-up (e.g.&#xD;
             for mental or geographical reasons, or patient is intravenous drug user or has strong&#xD;
             potential for non-compliance to medical regimes).&#xD;
&#xD;
          -  Patient is mentally unable to understand the nature, aims, or possible consequences of&#xD;
             the clinical investigation.&#xD;
&#xD;
          -  Patient has restricted legal capacity.&#xD;
&#xD;
          -  Patient did participate in another clinical investigation during the last 3 months.&#xD;
&#xD;
          -  Patient has revoked the consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Razvan Galalae, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Radiooncology and Radiotherapy, Evangelical Clinics Gelsenkirchen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for Radiooncology and Radiotherapy, Evangelical Clinics Gelsenkirchen</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>NRW</state>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>rectal toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

